Accriva HEMOCHRON Jr. ACT+

Land: Singapur

Sprache: Englisch

Quelle: HSA (Health Sciences Authority)

Verfügbar ab:

BIOMED DIAGNOSTICS PTE LTD

Klasse:

Class C IVD

Hergestellt von:

Accriva Diagnostics Inc.

Therapiebereich:

Hematology

Anwendungsgebiete:

The HEMOCHRON® Jr. ACT+ is a quantitative assay for monitoring heparin anticoagulation during various medical procedures. The ACT+ demonstrates linear correlation to the anticoagulation effects of heparin between 1.0 and 6.0 units/ml of blood. It is intended for use in monitoring moderate to high heparin doses frequently associated with cardiac catheterization and cardiopulmonary bypass surgery. The test is unaffected by aprotinin. The ACT+ is not sensitive to very low levels of heparin such as those encountered in critical care. The HEMOCHRON Jr. APTT and ACT-LR are available for monitoring low levels of heparin. The ACT+ test is performed on any HEMOCHRON Jr. model using a fresh whole blood sample. Each instrument is portable and intended for bedside use. The instrument is not intended for home use.

Produktbesonderheiten:

Models: Hemochron Jr. Signature Plus Whole Blood Coagulation System - PSIG, Hemochron ACT+ Cuvettes - JACT+, directCHECK Whole Blood Control - DCJACT-N, directCHECK Whole Blood Control - DCJACT-A

Berechtigungsdatum:

2011-11-09